AcelRx Pharmaceuticals(FRA) R5X

Market CapN/A

Since IPON/A

5 YearN/A

1 YearN/A

1 MonthN/A

N/A

AcelRx Pharmaceuticals Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.00

Net Income (TTM)

-$12.93

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

R5X News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Hayward, CA.

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Vincent J. Angotti, MBA

Website

talphera.com

R5X Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

N/A

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Payout Ratio

N/A

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

AcelRx Pharmaceuticals Performance Analysis

AcelRx Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 602,156	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 24,810	N/A

AcelRx Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD 5.44	N/A
2023	2023-12-31	USD -1.19	N/A
2024	2024-12-31	USD -0.47	-61.0%
2025	2025-12-31	USD -0.30	-35.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

N/A

Market Cap

N/A

Market Cap/Employee

$3.91

N/A

Employees

N/A

Net Income

-$3.71

+1.2%

EBITDA

-$3.37

+1.0%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$6.33

-44.1%

Total Debt

$5.68

+1.0%

Accounts Receivable

N/A

Inventory

$0.00

N/A

Long Term Debt

$5.68

+1.0%

Short Term Debt

$0.00

N/A

Return on Assets

-68.93%

+1.2%

Return on Invested Capital

-20.17%

N/A

Free Cash Flow

-$3.39

+1.4%

Operating Cash Flow

-$3.39

+1.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,684.24-0.00%

^DJIDJI

^DJIDJI$53,254.61-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,319.55-0.00%

BTCBitcoin

BTCBitcoin$78,890.00-0.00%

SPCXSPCX

SPCXSPCX$142.81+0.01%

AAPLAAPL

AAPLAAPL$315.25-0.01%

AMZNAMZN

AMZNAMZN$258.45-0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About R5X

What is the current price of AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals is trading at N/A per share.

What is the 52-week range for AcelRx Pharmaceuticals?

Over the past 52 weeks, AcelRx Pharmaceuticals has traded between N/A and N/A.

How much debt does AcelRx Pharmaceuticals have?

As of the most recent reporting period, AcelRx Pharmaceuticals reported total debt of $5.68M.

How much cash does AcelRx Pharmaceuticals have on hand?

AcelRx Pharmaceuticals reported $649.00K in cash and cash equivalents in its most recent financial results.

What is AcelRx Pharmaceuticals’s dividend yield?

AcelRx Pharmaceuticals does not currently have a dividend yield.

AcelRx Pharmaceuticals(FRA) R5X

AcelRx Pharmaceuticals Financials at a Glance

R5X News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About AcelRx Pharmaceuticals

R5X Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

AcelRx Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About R5X

What is the current price of AcelRx Pharmaceuticals?

What is the 52-week range for AcelRx Pharmaceuticals?

How much debt does AcelRx Pharmaceuticals have?

How much cash does AcelRx Pharmaceuticals have on hand?

What is AcelRx Pharmaceuticals’s dividend yield?

Premium Investing Services